Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Investing News Network
Douglas Flora: Pleased to Present the Future of Humanizing Cancer Care Through AI at ACCC Oncodaily
Blackstone and TPG-backed Hologic agrees deal for precision oncology firm Reveal Genomics PE Hub
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research BioSpace
A bank of biological samples from thousands of Brazilians could help the Unified Health System (SUS), which is public and free, identify people at higher risk of developing certain types of cancer. In the future, the SUS could offer these individuals more personalized prevention and screening strategies.
ECOG-ACRIN announces a national trial of ivonescimab for first-line treatment of advanced biliary tract cancer EurekAlert!
Азеносертиб: медиана общей выживаемости при раке яичников с положительным статусом циклина E1 — 15,8 месяца the Pharma Media
Азеносертиб: медиана общей выживаемости при раке яичников с положительным статусом циклина E1 — 15,8 месяца the Pharma Media
Ученые нашли в цитрусовых вещество, которое замедляет рост клеток рака легких Kursiv Media
Британец перепутал симптомы онкологии с простудой и чудом выжил после операции Главный Региональный
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Business Wire
Нанокапсулы найдут опухоль: вещество из известного овоща научили убивать устойчивые бактерии и рак Поиск - новости науки и техники
Детская онкология в Казахстане: выживаемость превысила 70% DKNews.kz
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter in The National Law Review